再鼎医药(ZLAB.US)涨逾5% Zoci有望成为其肿瘤领域首款全球上市产品

Core Insights - Zai Lab (ZLAB.US) shares rose over 5%, reaching $19.72, following the announcement of its strategic focus and clinical development progress at the 44th J.P. Morgan Healthcare Conference [1] Group 1: Company Developments - Zai Lab introduced its strategic priorities for 2026, highlighting the potential of Zocilurtatug pelitecan (Zoci) to become its first globally marketed product in the oncology field [1] - The company plans to initiate three pivotal registration studies by the end of 2026, targeting second-line and above small cell lung cancer, first-line small cell lung cancer, and neuroendocrine cancer [1]